{"id":"W3186399416","doi":"10.1158/1078-0432.ccr-21-1059","title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; bluebird bio; Agios Pharmaceuticals; TG Therapeutics; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; Legend Biotech; Celgene; AstraZeneca; Pfizer; Amgen; GlaxoSmithKline; Multiple Myeloma Research Foundation; Foundation for the National Institutes of Health","keywords":"Multiple myeloma; Medicine; Drug; Residual; Intensive care medicine; Minimal residual disease; Disease; Internal medicine; Pharmacology; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00241953,0.0001331996,0.000423337,0.0001172617,0.0001393758,0.00005617395,0.000131148,0.0001696991,0.00007933344],"category_scores_gemma":[0.005974604,0.0001180266,0.000158479,0.0003732372,0.0003840935,0.00008653885,0.0001516918,0.0007685636,0.00002670519],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001997021,"about_ca_system_score_gemma":0.003840469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007601547,"about_ca_topic_score_gemma":0.00260553,"domain_scores_codex":[0.9964135,0.0006180136,0.0008038203,0.0008782436,0.0007480093,0.0005384649],"domain_scores_gemma":[0.9953081,0.002192278,0.00007417328,0.0005612312,0.0007591938,0.001105032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005545774,0.0004558039,0.6897241,0.0002956635,0.00005406955,0.0002006044,0.0001070313,8.493309e-7,0.00006792024,0.0002115927,0.01495476,0.2883818],"study_design_scores_gemma":[0.009513898,0.0006751573,0.9515816,0.000191288,0.00005067925,0.000003167418,0.0003345551,0.0004096749,0.0002849308,0.0006423108,0.03619654,0.0001162191],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9719969,0.01076711,0.00007469158,0.01439138,0.0001194363,0.001912283,0.0000937548,0.00002699672,0.0006174454],"genre_scores_gemma":[0.9852455,0.00653179,0.001678468,0.0002157971,0.001484087,0.0006501324,0.000362662,0.0000312559,0.003800357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2882656,"threshold_uncertainty_score":0.715259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3248483922535994,"score_gpt":0.5827453539241509,"score_spread":0.2578969616705515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}